Biogen and Denali Therapeutics have announced that their experimental therapy for Parkinson’s disease has failed to demonstrate efficacy in a recent clinical trial.
The trial aimed to assess the drug's ability to slow the progression of this degenerative brain disorder but did not yield the desired results.
This outcome raises questions about the future of the therapy and its potential impact on the treatment landscape for Parkinson’s disease.